Focused On-demand Library for High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O60658

UPID:

PDE8A_HUMAN

Alternative names:

Alternative UPACC:

O60658; B3KXE6; H0YMZ7; Q6P9H3; Q969I1; Q96PC9; Q96PD0; Q96PD1; Q96T71; Q9UMB7; Q9UMC3

Background:

High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A plays a crucial role in hydrolyzing the second messenger cAMP, a pivotal regulator of numerous vital physiological processes. It is implicated in maintaining basal cyclic nucleotide levels and/or in cAMP regulation of germ cell development. Additionally, its interaction with RAF1 enhances RAF1-dependent EGF-activated ERK-signaling and offers protection against cell death induced by hydrogen peroxide and staurosporine.

Therapeutic significance:

Understanding the role of High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A could open doors to potential therapeutic strategies.